医学
细菌性阴道病
不利影响
背景(考古学)
重症监护医学
阴道炎
外阴阴道念珠菌病
免疫学
抗真菌
皮肤病科
妇科
内科学
生物
古生物学
作者
Yufei Wang,Zhaoxia Liu,Tingtao Chen
出处
期刊:Heliyon
[Elsevier]
日期:2024-03-01
卷期号:10 (5): e27239-e27239
标识
DOI:10.1016/j.heliyon.2024.e27239
摘要
Vulvovaginal candidiasis (VVC) is the second most common cause of vaginal infection globally after bacterial vaginosis (BV) and associated with adverse reproductive and obstetric outcomes, including preterm delivery, sexually transmitted infections and pelvic inflammatory disease. Although effective control of VVC is achievable with the use of traditional treatment strategies (i.e., antifungals), the possibility of drug intolerance, treatment failure and recurrence, as well as the appearance of antifungal-resistant Candida species remain critical challenges. Therefore, alternative therapeutic strategies against VVC are urgently required. In recent years, an improved understanding of the dysbiotic vaginal microbiota (VMB) during VVC has prompted the consideration of administering -biotics to restore the balance of the VMB within the context of VVC prevention and treatment. Here, we aim to summarize the current evidence of the anti-Candida effects of probiotics, postbiotics and synbiotics and their potential use as an alternative/complementary therapy against VVC. Additionally, this review discusses advantages and challenges associated with the application of -biotics in VVC to provide guidance for their later use. We also review new developments in VVC therapy, i.e., vaginal microbiota transplantation (VMT) as an emerging live biotherapeutic therapy against VVC and discuss existing shortcomings associated with this nascent field, expecting to stimulate further investigations for introduction of new therapies against VVC.
科研通智能强力驱动
Strongly Powered by AbleSci AI